Cargando…
The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
Background: Novel coronavirus infection (SARS CoV-2 or COVID-19) is associated with a high risk of thrombotic complications, including macro- and micro-thrombi in major organs, leading to increased morbidity and mortality. Anticoagulant use, mainly heparin, which has both anticoagulant and anti-infl...
Autores principales: | Bhoopat, Lantarima, Martynova, Anastasia, Choi, April, Pattharanitima, Pattharawin, Han, Semi, Du, Senxi, Syed, Ibrahim, Chan, Catherine, O'Neill, Caitlin, Oh, Esther, O'Connell, Casey L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330322/ http://dx.doi.org/10.1182/blood-2020-141732 |
Ejemplares similares
-
Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021) -
COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020) -
Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020) -
Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020) -
Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)